ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Alginate/Arabic gum-chitosan-encapsulated Bacillus subtilis enhances probiotic viability and alleviates liver injury and fibrosis in cholestatic rats.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synthesis and application of encapsulated Bifidobacterium Longum for mitigation of liver fibrosis via modulation of oxidative stress and inflammation in BDL rat model.World journal of microbiology & biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study investigates the effects of encapsulated Bacillus subtilis (B. subtilis) on liver injury and fibrosis in a cholestatic rat model. Probiotics like B. subtilis have shown anti-inflammatory and antioxidant properties, but their efficacy is reduced by the harsh gastrointestinal tract (GIT) environment. Some studies have shown that encapsulation using a combination of alginate, Arabic gum, and chitosan can improve probiotic viability and promote controlled release in the intestine. In this study, male Wistar rats were randomly assigned to five groups: healthy control, cholestasis control, probiotic, free capsule, and encapsulated probiotic, to evaluate the protective effects of the encapsulated probiotic against cholestasis-induced damage. Encapsulated B. subtilis with the dosage of 3 × 10
Indexed as
Identifiers
40694095What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.